The global diabetes devices and drugs market will expand at a moderate CAGR of 5.90% during the forecast period from 2013 to 2019, according to a report from Transparency Market Research (TMR). This report is titled “Diabetes Devices and Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019”. In 2012, the global diabetes devices and drugs market was worth more than US$54.0 bn and by 2019, the market is projected to be worth US$83.0 bn.
Browse the full Diabetes Devices and Drugs Market (Devices: Diagnostic & Monitoring and Insulin Delivery Devices, Drugs: Insulin Derivatives, GLP-1 and OADs) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 report at http://www.transparencymarketresearch.com/diabetes-devices-market.html
The global diabetes devices and drugs market is driven primarily by the expanding diabetic population around the world. In 2014, the global prevalence of diabetes was recorded to be 9% among adults of age 18 years and older, says the WHO. In addition to this, extensive R&D activities are resulting in turnaround changes in the global diabetes devices and drugs market. The global diabetes devices and drugs market will also benefit from the increasing technological innovation and the rising demand for self-monitoring and insulin delivery devices.
However, there are certain hurdles that will suppress the growth of the market. These include: Unfavorable reimbursement policies, patent expiry, depleting profit margins, high diagnosis and treatment cost, and hard entry barriers discouraging new players from penetrating the market.By device type, the global diabetes devices and drugs market is divided into diabetes monitoring and diagnostic devices (continuous glucose monitoring devices, analog glucose meters, glucose test strips, lancets and lancing devices, and others) and insulin delivery devices (insulin injectors, insulin pumps, insulin pens, and insulin syringes). By 2019, the segment of test strips is projected to emerge as the leading segment. On the other hand, the segment of continuous glucose monitoring devices is expected to demonstrate the fastest growth during the forecasting horizon.
Therapy-wise, the global diabetes devices and drugs market is segmented into insulin, non-insulin injectable anti-diabetes drugs, and oral anti-diabetes drugs. Long-acting insulin derivatives held a share of 42.7% in the global diabetes devices and drugs market in 2012. Among oral anti-diabetes drugs, the SGLT-2 inhibitors segment will witness a remarkable CAGR of 76.80% during the forecast period.
On the basis of geography, the global diabetes devices and drugs market is classified into Asia Pacific, Europe, North America, and Rest of the World (RoW). North America is leading the global diabetes devices and drugs market due to the growing diabetic population and rising demand for novel devices and high-quality drugs. Nevertheless, it is Asia Pacific that is projected to witness the highest growth during the forecast period. The Asia Pacific diabetic devices and drugs market will be driven by its rising diabetic population, growing awareness regarding self-monitoring of diabetes, elevated medical expenditure, and rising penetration of healthcare technology.
Players in the global diabetes devices and drugs market will benefit from the opportunity presented by the development of new formulations of insulin. Moreover, development of non-invasive diabetes diagnostic and drug delivery devices will offer new market leads. The most established players in the global diabetes devices and drugs market are Abbott Laboratories, B. Braun Melsungen, AstraZeneca, Bayer HealthCare, DexCom, and Eli Lilly and Company.
Key Segments of the Global Diabetes Devices Market
Global Diabetes Devices Market, by Devices
- Diabetes Monitoring and diagnostic devices
- Analog glucose meter
- Glucose Test strips
- Lancets and Lancing devices
- Continuous glucose monitoring devices
- Insulin Delivery Devices
- Insulin Syringes
- Insulin Pens
- Insulin Pumps
- Insulin Injectors
Global Diabetes Drugs Market, by Therapy
- Short-acting insulin derivatives
- Intermediate-acting insulin derivatives
- Long-acting insulin derivatives
- Rapid-acting insulin derivatives
- Premixed insulin derivatives
- Oral anti-diabetes drugs class
- Alpha-glucosidase inhibitors
- DPP-4 inhibitors
- SGLT-2 inhibitors
- Non-insulin injectable anti-diabetes drugs
- GLP-1 analogs
Global Diabetes Drugs Market, by Geography
- North America
- Rest of the World (RoW)
Browse : Our new press releases http://www.transparencymarketresearch.com/pressrelease/global-diabetes-devices-market.htm
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453